2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 930

Joint Location-Specific IL6 and JAK-STAT Signaling in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS)
Abstract Number: 931

Patients with Seropositive Rheumatoid Arthritis Who Do Not Mount a CRP Response When They Have Synovitis Are Immunologically Distinct and Are Poorly Served By Current Management Strategies
Abstract Number: 932

Fibroblasts Senescence Is Observed in Rheumatoid and Osteoarthritic Synovial Tissues and Triggers a Pro-Inflammatory Program Ex Vivo
Abstract Number: 933

Inflammation in the Hippocampus Affects Insulin-like Growth Factor-1 Receptor Signaling and Contributes to Neurological Sequelae in Rheumatoid Arthritis
Abstract Number: 934

HIV Protease Inhibitors Cure Lupus-Prone Mice and Prevent T Helper 17 Cell-Driven Inflammation By Inhibiting CD95-Non-Apoptotic Signaling Pathway
Abstract Number: 935

Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Lipocalin-2
Abstract Number: 936

Selective Deficiency of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in T Lymphocytes Leads to mTORC1 Activation, Treg Dysfunction and Systemic Autoimmune Disease
Abstract Number: 937

Evidence of a Common Microglial Signature in Models of ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’
Abstract Number: 938

Dermal Lymphatic Dysfunction and Photosensitivity in the MRL/Lpr Lupus Model
Abstract Number: 939

Rab4A Protects from Lupus Nephritis By Limiting Germinal Center Formation and Pro-Inflammatory Expression of GLUT1 and Integrin By Renal Epithelial Cells
Abstract Number: 940

Inactivated Influenza Vaccine Prevents Respiratory Infections and Improves All-Cause and Cause-Specific Mortality in Immunosuppressed People with Autoimmune Rheumatic Diseases: Propensity Score Adjusted Cohort Study Using Data from Clinical Practice Research Datalink
Abstract Number: 941

Causal Inference Methods for the Effect of Rheumatoid Arthritis on Mortality Independent of Lifestyle and Clinical Factors before and after RA Diagnosis
Abstract Number: 942

Risk of Serious Infections in Tocilizumab Versus TNF Inhibitor Initiators in Patients with RA: A Multi-Database Cohort Study
Abstract Number: 943

Risk of Prostate Cancer in US Veterans with Rheumatoid Arthritis
Abstract Number: 944

Gout: A Potential Risk Factor for Uveitis in the Older Adults?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].